Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Follicular 8Lymphoma 8Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Recurrence 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Bendamustine Hydrochloride × 90 days × Clear all
NCT06522737 2026-04-06

TERZO

SecuraBio

Phase 3 Recruiting
124 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡